Sutro Biopharma (STRO) Cash & Current Investments (2017 - 2025)

Sutro Biopharma (STRO) has 9 years of Cash & Current Investments data on file, last reported at $141.4 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Current Investments fell 55.37% year-over-year to $141.4 million; the trailing twelve-month figure through Dec 2025 stood at $141.4 million (down 55.37% YoY), and the FY2025 full-year result was $141.4 million, down 55.37% from the prior year.
• Cash & Current Investments retreated to $141.4 million in Q4 2025, from $167.6 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $388.3 million in Q3 2024 to a low of $66.6 million in Q1 2022.
• A 5-year average of $218.5 million and a median of $212.7 million in 2021 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments slumped 69.74% in 2022 and soared 277.32% in 2023, its largest moves.
• Tracing STRO's Cash & Current Investments over 5 years: stood at $160.8 million in 2021, then soared by 88.08% to $302.3 million in 2022, then tumbled by 63.22% to $111.2 million in 2023, then soared by 184.96% to $316.9 million in 2024, then plunged by 55.37% to $141.4 million in 2025.
• Business Quant data shows STRO's Cash & Current Investments at $141.4 million in Q4 2025, $167.6 million in Q3 2025, and $205.1 million in Q2 2025.